Department of Chemistry, Savitribai Phule Pune University (Formerly University of Pune), Pune, India.
Serum Institute of India Pvt. Limited, Pune, India.
J Biomol Struct Dyn. 2020 Jun;38(9):2717-2736. doi: 10.1080/07391102.2019.1645735. Epub 2019 Aug 1.
Sickle cell disease is an inherited disease caused by point mutation in hemoglobin (β-globin gene). Under oxygen saturation, sickle hemoglobin form polymers, leading to rigid erythrocytes. The transition of the blood vessels is altered and initiated by the adhesion of erythrocytes, neutrophils and endothelial cells. Sickle Hemoglobin (HbS) polymerization is a major cause in red blood cells (RBC), promoting sickling and destruction of RBCs. Isoquercitrin, a medicinal bioactive compound found in various medicinal plants, has multiple health benefits. The present study examines the potential of isoquercitrin as an anti-sickle agent, showing a significant decrease in the rate of polymerization as well as sickling of RBCs. Isoquercitrin-induced graded alteration in absorbance and fluorescence of HbS, confirmed their interaction. A negative value of Δ° strongly suggests that it is a spontaneous exothermic reaction induced by entropy. Negative Δ° and positive Δ° predicted that hydrogen and hydrophobic binding forces interfered with a hydrophobic microenvironment of β6Val leading to polymerization inhibition of HbS. HbS-Isoquercitrin complex exhibits helical structural changes leading to destabilization of the HbS polymer as confirmed by CD spectroscopy. MST and DSC results indicate greater changes in thermophoretic mobility and thermal stability of sickle hemoglobin in the presence of isoquercitrin, respectively. These findings were also supported by molecular simulation studies using DOCK6 and GROMACS. Hence, we can conclude that isoquercitrin interacts with HbS through hydrogen bonding, which leads to polymerization inhibition. Consequently, isoquercitrin could potentially be used as a medication for the treatment of sickle cell disease.Communicated by Ramaswamy H. Sarma.
镰状细胞病是一种由血红蛋白(β-球蛋白基因)点突变引起的遗传性疾病。在氧饱和度下,镰状血红蛋白形成聚合物,导致红细胞刚性化。血管的转变是由红细胞、嗜中性粒细胞和内皮细胞的黏附引发的。镰状血红蛋白(HbS)聚合是红细胞(RBC)中的一个主要原因,促进镰状化和 RBC 的破坏。异槲皮苷,一种在各种药用植物中发现的药用生物活性化合物,具有多种健康益处。本研究检查了异槲皮苷作为抗镰状细胞药物的潜力,显示出 RBC 聚合率和镰状化率的显著降低。异槲皮苷诱导 HbS 吸光度和荧光的分级变化,证实了它们的相互作用。Δ°的负值强烈表明这是由熵引起的自发放热反应。负的Δ°和正的Δ°预测氢键和疏水键合力干扰β6Val 的疏水环境,导致 HbS 聚合抑制。HbS-异槲皮苷复合物表现出螺旋结构变化,导致 HbS 聚合物的不稳定性,这一点通过 CD 光谱得到证实。MST 和 DSC 结果表明,在存在异槲皮苷的情况下,镰状血红蛋白的热迁移率和热稳定性有更大的变化。这些发现也得到了使用 DOCK6 和 GROMACS 的分子模拟研究的支持。因此,我们可以得出结论,异槲皮苷通过氢键与 HbS 相互作用,从而导致聚合抑制。因此,异槲皮苷有可能被用作治疗镰状细胞病的药物。